{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:59:29Z","timestamp":1791662369417,"version":"4.3.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>There are few studies assessing the association of tumor mutational burden (TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers.<\/jats:p><\/jats:sec>Objective<\/jats:title>To clinically validate a TMB biomarker from a next-generation sequencing targeted gene panel assay.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A prespecified cohort study using the deidentified clinicogenomic Tempus database of patients sequenced between 2018 and 2022, which contained retrospective, observational data originating from 300 cancer sites including 199 community sites and 101 academic sites. Patients with advanced solid tumors across 8 cancer types and more than 20 histologies, sequenced with Tempus xT who were treated with immune checkpoint inhibitors (ICIs) in the first-line or second-line setting were included. Data were analyzed from September 2018 to August 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Treatment with US Food and Drug Administration (FDA)\u2013approved antiprogrammed cell death-1\/programmed cell death-ligand 1 (PD-1\/PD-L1) ICI and\/or in combination with a cytotoxic T-lymphocyte-associated protein-4 ICI.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the association of tumor mutational burden (TMB) binary category (high [\u226510 mut\/mb] vs low) with overall survival (OS) in patients treated with ICIs. Secondary outcomes were progression-free survival (PFS), and time to progression (TTP).<\/jats:p><\/jats:sec>Results<\/jats:title>In the evaluable cohort of 674 patients, the median (IQR) age was 69.4 (28.6-89.8) years, 271 patients (40.2%) were female, and 435 patients (64.5%) were White. The most common advanced cancers were non\u2013small cell lung cancer (330 patients [49.0%]), followed by bladder cancer (148 patients [22.0%]), and head and neck squamous cell carcinoma (96 patients [14.8%]). Median (IQR) follow-up was 7.2 (3.2-14.1) months. High TMB (TMB-H) cancers (206 patients [30.6%]) were significantly associated with longer OS than low TMB (TMB-L) cancers (hazard ratio [HR], 0.72; upper confidence bound [UCB], 0.91; P<\/jats:italic>\u2009=\u2009.01). In a prospective subset of 403 patients treated with ICIs after TMB testing, TMB-H cancers (135 patients [33.5%]) were significantly associated with longer OS (HR, 0.61; UCB, 0.84; P<\/jats:italic>\u2009=\u2009.005), PFS (HR, 0.62; UCB, 0.82; P<\/jats:italic>\u2009=\u2009.003), and TTP (HR, 0.67; UCB, 0.92; P<\/jats:italic>\u2009=\u2009.02) than TMB-L cancers. An overall survival benefit was seen regardless of the type of ICI used (pembrolizumab, 339 patients; HR, 0.67; UCB, 0.94; P<\/jats:italic>\u2009=\u2009.03), other ICIs (64 patients; HR, 0.37; UCB, 0.85; P<\/jats:italic>\u2009=\u2009.03), and after adjusting for PD-L1 and microsatellite stability status (403 patients; HR\u2009=\u20090.67; UCB, 0.92; P<\/jats:italic>\u2009=\u2009.02).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with advanced solid tumors treated with ICIs in diverse clinics, TMB-H cancers were significantly associated with improved clinical outcomes compared with TMB-L cancers.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.11181","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:02:59Z","timestamp":1683039779000},"page":"e2311181","source":"Crossref","is-referenced-by-count":140,"title":["Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Charu","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Ben-Shachar","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Gao","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Hyun","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Rivers","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Epstein","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiyana","family":"Kaneva","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chithra","family":"Sangli","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Nimeiri","sequence":"additional","affiliation":[{"name":"Tempus Labs, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Patel","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"zoi230353r1","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy.","volume":"8","author":"Efremova","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"zoi230353r2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity.","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"zoi230353r3","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"zoi230353r4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types.","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"5","key":"zoi230353r5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi230353r6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression Levels.","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"issue":"21","key":"zoi230353r7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230353r8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230353r9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"17","key":"zoi230353r10","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors.","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"zoi230353r12","doi-asserted-by":"publisher","first-page":"v916","DOI":"10.1093\/annonc\/mdz394.077","article-title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials.","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi230353r13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi230353r14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41416-020-0762-5","article-title":"Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples.","volume":"122","author":"Mankor","year":"2020","journal-title":"Br J Cancer"},{"issue":"24","key":"zoi230353r15","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.v10i24","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"zoi230353r16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer.","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"2","key":"zoi230353r17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00262-022-03252-y","article-title":"Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.","volume":"72","author":"Gao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"zoi230353r18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"zoi230353r19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/gcc.v58.8","article-title":"Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"zoi230353r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi230353r22","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/j.amepre.2021.05.007","article-title":"Racial and ethnic disparities in clinical trial recruitment in the U.S.","volume":"61","author":"Hong","year":"2021","journal-title":"Am J Prev Med"},{"key":"zoi230353r20","author":"Johnson","year":"2021"},{"key":"zoi230353r11","unstructured":"US Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. June 17, 2020. Accessed October 5, 2022. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804390\/aggarwal_2023_oi_230353_1682344042.69204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:03:05Z","timestamp":1683039785000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.11181","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}